Stock Research for ALPMF

ALPMF
Current Price

$13.6000


Latest Update: 2018-02-12 09:51:00

High
$ 13.6000
Low
$ 13.6000
Close
$ 13.6000
Volume
300
 
  

Featured Broker: TradeStation

Get the due diligence for another stock.

 

ALPMF Stock Chart & Research Data

The ALPMF chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ALPMF chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ALPMF Due diligence Resources & Stock Charts

The ALPMF stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ALPMF Detailed Price Forecast - CNN Money CNN View ALPMF Detailed Summary - Google Finance
Yahoo View ALPMF Detailed Summary - Yahoo! Finance Zacks View ALPMF Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View ALPMF Trends & Analysis - Trade-Ideas Barrons View ALPMF Major Holders - Barrons
NASDAQ View ALPMF Call Transcripts - NASDAQ Seeking View ALPMF Breaking News & Analysis - Seeking Alpha
Spotlight View ALPMF Annual Report - CompanySpotlight.com OTC Report View ALPMF OTC Short Report - OTCShortReport.com
TradeKing View ALPMF Fundamentals - TradeKing Charts View ALPMF SEC Filings - Bar Chart
WSJ View Historical Prices for ALPMF - The WSJ Morningstar View Performance/Total Return for ALPMF - Morningstar
MarketWatch View the Analyst Estimates for ALPMF - MarketWatch CNBC View the Earnings History for ALPMF - CNBC
StockMarketWatch View the ALPMF Earnings - StockMarketWatch MacroAxis View ALPMF Buy or Sell Recommendations - MacroAxis
Bullish View the ALPMF Bullish Patterns - American Bulls Short Pains View ALPMF Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View ALPMF Stock Mentions - StockTwits PennyStocks View ALPMF Stock Mentions - PennyStockTweets
Twitter View ALPMF Stock Mentions - Twitter Invest Hub View ALPMF Investment Forum News - Investor Hub
Yahoo View ALPMF Stock Mentions - Yahoo! Message Board Seeking Alpha View ALPMF Stock Mentions - Seeking Alpha




Financial & Transaction Holdings

SECform4 View Insider Transactions for ALPMF - SECform4.com Insider Cow View Insider Transactions for ALPMF - Insider Cow
CNBC View ALPMF Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ALPMF - OTC Markets
Yahoo View Insider Transactions for ALPMF - Yahoo! Finance NASDAQ View Institutional Holdings for ALPMF - NASDAQ


Stock Charts

FinViz View ALPMF Stock Insight & Charts - FinViz.com StockCharts View ALPMF Investment Charts - StockCharts.com
BarChart View ALPMF Stock Overview & Charts - BarChart Trading View View ALPMF User Generated Charts - Trading View


Latest Financial News for ALPMF

ETFs with exposure to Astellas Pharma, Inc. : December 8, 2017
Posted on Friday December 08, 2017

Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Astellas Pharma, Inc. Here are 5 ETFs with the largest exposure to ALPMF-US. Comparing the performance and risk of Astellas Pharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)


ETFs with exposure to Astellas Pharma, Inc. : November 16, 2017
Posted on Thursday November 16, 2017

Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Astellas Pharma, Inc. Here are 5 ETFs with the largest exposure to ALPMF-US. Comparing the performance and risk of Astellas Pharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)


Astellas faces U.S. probe over patient assistance charity support
Posted on Wednesday November 15, 2017

Astellas Pharma Inc has become the latest company to reveal it has become the subject of a U.S. probe into drugmakers' financial support of charities offering assistance to Medicare patients seeking help to cover out-of-pocket drug costs. In a lawsuit filed on Monday in federal court in Chicago against its insurers, a unit of Japan's Astellas, said the U.S. Justice Department was conducting a joint criminal and civil investigation of the company, its officers and its employees. Astellas US Holdings Inc said it first received a subpoena from the Justice Department in March 2016 in connection with the industry-wide probe and on Oct. 26 entered into an agreement that essentially allows for an extension of the statute of limitations.


Astellas Pharma, Inc. :ALPMF-US: Earnings Analysis: Q2, 2018 By the Numbers : November 15, 2017
Posted on Wednesday November 15, 2017

Categories: Yahoo FinanceGet free summary analysis Astellas Pharma, Inc. reports financial results for the quarter ended September 30, 2017. Highlights Summary numbers: Revenues of USD 2,858.48 million, Net Earnings of USD 357.32 million. Gross margins widened from 73.41% to 75.25% compared to the same period last year, operating (EBITDA) margins now 27.72% from 28.15%. Change in operating ... Read more (Read more...)


Astellas Pharma buying Universal Cells for $102M in Seattle's third biotech ...
GeekWire - Feb 15, 2018
“We are thrilled to be able to leverage the full potential of our Universal Donor Cell technology by becoming an intrinsic part of Astellas' effort to fulfill the promises of regenerative medicine to treat diseases,” Claudia Mitchell, Universal Cells ...

Astellas acquires Universal Cells for up to $102.5M
Seeking Alpha - Feb 14, 2018
Astellas Pharma (OTCPK:ALPMF) has acquired Seattle, WA-based Universal Cells, Inc. and its Universal Donor Cell technology enabling the creation of cell therapy products that do not require human leukocyte antigen (HLA) matching which greatly reduces ...
Astellas Acquires Universal Cells, Inc. - PR Newswire (press release)
Japan's Astellas Pharma acquires US biotech firm Universal Cells for $102.5m - DEALSTREETASIA

Astellas Pharma expands portfolio by acquiring Universal Cells
Life Sciences Intellectual Property Review - Feb 16, 2018
In October 2017, the Astellas Institute for Regenerative Medicine entered into an exclusive licence agreement with Universal Cells to use universal donor cell technology in a single indication.

Astellas Pharma's DNA vaccine candidate flunks late-stage study in CMV ...
Seeking Alpha - Jan 22, 2018
Astellas Pharma (OTCPK:ALPMF) and licensor Vical (NASDAQ:VICL) announce that Astellas' investigational DNA vaccine candidate, Orphan Drug-tagged ASP0113, failed to achieve the primary endpoint and secondary endpoints in a Phase 3 clinical trial, HELIOS ...
Astellas and Vical Announce Top-Line Results for Phase 3 Trial of ... - PR Newswire (press release)
Second time also unlucky for Astellas and Vical's herpes vaccine - The Pharma Letter

Enter a stock symbol to view the stock details.